Unknown

Dataset Information

0

Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy.


ABSTRACT: The binding of plasma proteins to nanomedicines is widely considered detrimental to their delivery to tumors. Here, the design of OxPt/SN38 nanoparticle containing a hydrophilic oxaliplatin (OxPt) prodrug in a coordination polymer core and a hydrophobic cholesterol-conjugated SN38 prodrug on the lipid shell for active tumor targeting is reported. OxPt/SN38 hitchhikes on low-density lipoprotein (LDL) particles, concentrates in tumors via LDL receptor-mediated endocytosis, and selectively releases SN38 and OxPt in acidic, esterase-rich, and reducing tumor microenvironments, leading to 6.0- and 4.9-times higher accumulations in tumors over free drugs. By simultaneously crosslinking DNA and inhibiting topoisomerase I, OxPt/SN38 achieved 92-98% tumor growth inhibition in five colorectal cancer tumor models and prolonged mouse survival by 58-80 days compared to free drug controls in three human colorectal cancer tumor models without causing serious side effects. The study has uncovered a novel nanomedicine strategy to co-deliver combination chemotherapies to tumors via active targeting of the LDL receptor.

SUBMITTER: Jiang X 

PROVIDER: S-EPMC9404402 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy.

Jiang Xiaomin X   Han Wenbo W   Liu Jianqiao J   Mao Jianming J   Lee Morten J MJ   Rodriguez Megan M   Li Youyou Y   Luo Taokun T   Xu Ziwan Z   Yang Kaiting K   Bissonnette Marc M   Weichselbaum Ralph R RR   Lin Wenbin W  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20220624 24


The binding of plasma proteins to nanomedicines is widely considered detrimental to their delivery to tumors. Here, the design of OxPt/SN38 nanoparticle containing a hydrophilic oxaliplatin (OxPt) prodrug in a coordination polymer core and a hydrophobic cholesterol-conjugated SN38 prodrug on the lipid shell for active tumor targeting is reported. OxPt/SN38 hitchhikes on low-density lipoprotein (LDL) particles, concentrates in tumors via LDL receptor-mediated endocytosis, and selectively releases  ...[more]

Similar Datasets

| S-EPMC4077779 | biostudies-literature
| S-EPMC6513513 | biostudies-literature
| S-EPMC7170936 | biostudies-literature
| S-EPMC5245982 | biostudies-literature
| S-EPMC3071079 | biostudies-other
| S-EPMC6263114 | biostudies-literature
| S-EPMC7747060 | biostudies-literature
| S-EPMC3728361 | biostudies-literature
| S-EPMC2843502 | biostudies-literature
| S-EPMC5812013 | biostudies-literature